Company Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer in the United States and internationally.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma.
In addition, it engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center, and MSK and Massachusetts Institute of Technology to develop and commercialize licensed products.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Michael Rossi |
Contact Details
Address: 230 Park Avenue, Suite 3350 New York, New York 10169 United States | |
| Phone | 646 885 8505 |
| Website | ymabs.com |
Stock Details
| Ticker Symbol | YMAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001722964 |
| CUSIP Number | 984241109 |
| ISIN Number | US9842411095 |
| Employer ID | 47-4619612 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Rossi | Chief Executive Officer, President and Director |
| Thomas Gad | Founder, Chief Business Officer and Vice Chairman |
| Peter P. Pfreundschuh CPA | Chief Financial Officer and Treasurer |
| Joris Wiel Jan Wilms | Senior Vice President and Chief Operating Officer |
| Dr. Torben Lund-Hansen M.Sc., Ph.D. | Senior Vice President and Chief Technology Officer |
| Courtney Dugan | Vice President of Investor Relations |
| John W. LaRocca Esq. | General Counsel and Chief Legal Officer |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Development Officer |
| Doug Gentilcore | Senior Vice President and Head of DANYELZA Business Unit |
| Natalie Tucker | Senior Vice President and Radiopharmaceutical Business Unit Head |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | 144 | Filing |
| Mar 7, 2025 | 144 | Filing |
| Mar 7, 2025 | 144 | Filing |
| Mar 7, 2025 | 144 | Filing |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 424B5 | Filing |
| Mar 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |